Past Issues

2019: Volume 2, Issue 1

Triple Hormonal Blockade (ADT3): A Patient’s Perspective

Charles Maack*

US Too International Inc, USA

Corresponding Author: Charles Maack, US Too International Inc, 5003 Fairview Ave, Downers Grove, IL 60515, USA

Received: January 23, 2019
Published: January 30, 2019

Copyright: ©2019 Maack C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium provided the original author and source are credited.

Citation: Maack C. (2019). Primary Renal Lymphoma: A Case Report. Oncogen 2(1): 6.

Opinion

The information below is a lengthy read, but for men moved to androgen deprivation therapy the information is extremely important to be aware since everything explained may be involved in their well-being. Please take the important time to thoroughly read, take notes, and become knowledgeable in your treatment.  Anyone moved to androgen deprivation therapy, and particularly anyone with already known advanced and metastasized prostate cancer SHOULD NOT be prescribed only a GnRH agonist or antagonist as monotherapy.  There is significant data available of the role that the androgen receptor plays in prostate cancer cell growth and proliferation, thus medication - known as an antiandrogen - to block testosterone access via androgen receptors to the nucleus on prostate cancer cells should be included as part of androgen deprivation therapy.   For men prescribed chemotherapy to be accompanied by continued androgen deprivation therapy, the antiandrogen becomes additionally important since it serves to enhance the effectiveness of the chemotherapy medication docetaxel/Taxotere.

Suggested For You

©2018 Magnus Med Club Ltd. All rights Reserved. Oncogen is an Independent Peer-Reviewed Cancer Journal. Terms of ServicePrivacy Policy